IP Library › Granted Patent US 12,661,516
Granted Patent B2
US 12,661,516 · App. 18/747,310 · Granted Jun 23, 2026

Treatment of neurodegenerative disease with high frequency stimulation, and associated systems and methods

Inventors: James R. Thacker (Homer, AK); Kerry Bradley (Glendale, CA); Dongchul Lee (Agua Dulce, CA)
Assignee: Nevro Corporation
A61N1/36171A61N1/06A61N1/36062A61N1/36082A61N1/36175
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,661,516
App. No.
18/747,310
Granted
Jun 23, 2026
Kind
B2
Abstract

Systems and methods for treating neurodegenerative disorders with high frequency stimulation are disclosed. A representative method for treating a patient includes applying an electrical signal to the patient via a treatment system that includes a signal delivery element positioned at or within a white matter of the patient's brain, spinal cord, or both, the electrical signal having a frequency of from about 1.5 kHz to about 100 kHz.

Claims (30)

1 . A method for treating a neurodegenerative disease in a patient, the method comprising:

programming a signal generator to deliver an electrical signal to the patient via a signal delivery element positioned at or within white matter of the patient's brain,

wherein the electrical signal has a frequency within a frequency range of from about 5 kHz to about 100 kHz, and

wherein the electrical signal addresses the patient's neurodegenerative disease.

2 . The method of claim 1 wherein the electrical signal modulates one or more glial cells present in the white matter at or proximate the signal delivery element.

3 . The method of claim 2 wherein the one or more glial cells include one or more astrocytes.

4 . The method of claim 1 wherein the electrical signal has a frequency of at least 50 KHz.

5 . The method of claim 1 wherein the electrical signal has a pulse width in a pulse width range of from about 10 microseconds to about 30 microseconds.

6 . The method of claim 1 wherein the electrical signal does not induce paresthesia in the patient.

7 . The method of claim 1 wherein the electrical signal modulates ion-pump activity of one or more neurons and/or glial cells within the white matter of the brain without the use of ATP.

8 . The method of claim 1 wherein the neurodegenerative disease includes Parkinson's disease.

9 . The method of claim 1 wherein the signal delivery element is positioned at or proximate a degenerative lesion within the white matter of the patient's brain.

10 . The method of claim 9 wherein programming the signal generator is performed at least partially in response to an indication of the degenerative lesion.

11 . A method for treating a neurodegenerative disease in a patient, the method comprising:

programming a signal generator to deliver an electrical signal to one or more glial cells of the patient via a signal delivery element positioned at or within white matter of the patient's brain,

wherein the electrical signal has a frequency within a frequency range of from about 5 kHz to about 100 kHz, and

wherein the electrical signal modulates ion-pump activity of the one or more glial cells within the white matter of the brain without the use of ATP to address the neurodegenerative disease of the patient.

12 . The method of claim 11 wherein the one or more glial cells include one or more astrocytes.

13 . The method of claim 11 wherein the frequency is at least 50 KHz.

14 . A system for treating a neurodegenerative disease in a patient, the system comprising:

a signal delivery element configured to be positioned at or within white matter of the patient's brain; and

a signal generator programmed with instructions that, when executed, cause the signal generator to deliver an electrical signal to the white matter of the patient's brain via the signal delivery element, wherein the electrical signal has a frequency within a frequency range of from about 5 kHz to about 100 kHz, and wherein the electrical signal addresses the patient's neurodegenerative disease.

15 . The system of claim 14 wherein the signal delivery element is configured to be positioned proximate one or more glial cells within the white matter such that the electrical signal modulates the one or more glial cells.

16 . The system of claim 15 wherein the one or more glial cells include one or more astrocytes.

17 . The system of claim 14 wherein the signal delivery element is configured to be positioned at or proximate a degenerative lesion within the white matter of the patient's brain.

18 . The system of claim 14 wherein the electrical signal has a frequency of at least 50 kHz.

19 . The system of claim 14 wherein the electrical signal has a pulse width in a pulse width range of from about 10 microseconds to about 30 microseconds.

20 . The system of claim 14 wherein the electrical signal does not induce paresthesia in the patient.

21 . The system of claim 14 wherein, when administered, the electrical signal modulates ion-pump activity of one or more neurons and/or glial cells within the white matter of the brain without the use of ATP.

22 . The system of claim 14 wherein the neurodegenerative disease includes Parkinson's disease.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2024
From: THACKER, JAMES R.; BRADLEY, KERRY; LEE, DONGCHUL
To: NEVRO CORP.
Reel/Frame 069077/0500 →
Continuity (4)
Continuation 17410953 · Aug 24, 2021
Continuation 15798110 · Oct 30, 2017
Provisional Application 62415429 · Oct 31, 2016
Related Publication 20250050112A1 · Feb 13, 2025
References Cited (68)
US 5683422A · Rise · 1997 [cited by applicant]
US 5707396A · Benabid · 1998 [cited by applicant]
US 7313442B2 · Velasco et al. · 2007 [cited by applicant]
US 7346395B2 · Lozano et al. · 2008 [cited by applicant]
US 7653433B2 · Lozano et al. · 2010 [cited by applicant]
US 8190264B2 · Lozano et al. · 2012 [cited by applicant]
US 8195298B2 · Lozano et al. · 2012 [cited by applicant]
US 8280514B2 · Lozano et al. · 2012 [cited by applicant]
US 8315703B2 · Lozano et al. · 2012 [cited by applicant]
US 8355797B2 · Caparso et al. · 2013 [cited by applicant]
US 8428735B2 · Littlewood · 2013 [cited by applicant]
US 8467878B2 · Lozano et al. · 2013 [cited by applicant]
US 8712533B2 · Alataris et al. · 2014 [cited by applicant]
US 8798754B2 · Knudson et al. · 2014 [cited by applicant]
US 8849392B2 · Lozano et al. · 2014 [cited by applicant]
US 8909342B2 · Lozano et al. · 2014 [cited by applicant]
US 9278215B2 · Thacker et al. · 2016 [cited by applicant]
US 9327121B2 · Thacker et al. · 2016 [cited by applicant]
US 9446238B2 · Lozano et al. · 2016 [cited by applicant]
US 9884198B2 · Parker · 2018 [cited by applicant]
US 9895539B1 · Heit et al. · 2018 [cited by applicant]
US 10493275B2 · Alataris et al. · 2019 [cited by applicant]
US 10751536B1 · Heit et al. · 2020 [cited by applicant]
US 11123549B1 · Pannu · 2021 [cited by applicant]
US 11123565B1 · Thacker · 2021 [cited by examiner]
US 11446504B1 · Lee · 2022 [cited by applicant]
US 20040111127A1 · Gliner · 2004 [cited by applicant]
US 20050197678A1 · Bojeva · 2005 [cited by applicant]
US 20060004422A1 · DeRidder et al. · 2006 [cited by applicant]
US 20060015153A1 · Gliner · 2006 [cited by applicant]
US 20060155348A1 · deCharms · 2006 [cited by applicant]
US 20060161218A1 · Danilov · 2006 [cited by applicant]
US 20090054829A1 · Chen · 2009 [cited by applicant]
US 20090204173A1 · Fang et al. · 2009 [cited by applicant]
US 20100191307A1 · Fang et al. · 2010 [cited by applicant]
US 20100274312A1 · Alataris et al. · 2010 [cited by applicant]
US 20100274317A1 · Parker et al. · 2010 [cited by applicant]
US 20110071593A1 · Parker et al. · 2011 [cited by applicant]
US 20120065699A1 · Bedenbaugh · 2012 [cited by applicant]
US 20120172946A1 · Alataris et al. · 2012 [cited by applicant]
US 20130066411A1 · Thacker et al. · 2013 [cited by applicant]
US 20140207207A1 · Alataris et al. · 2014 [cited by applicant]
US 20140316497A1 · Gaunt et al. · 2014 [cited by applicant]
US 20150217116A1 · Parramon et al. · 2015 [cited by applicant]
US 20160175594A1 · Min · 2016 [cited by applicant]
US 20170165485A1 · Sullivan et al. · 2017 [cited by applicant]
US 20170216587A1 · Parker · 2017 [cited by applicant]
US 20170281949A1 · Thacker et al. · 2017 [cited by applicant]
US 20180280691A1 · Ackermann et al. · 2018 [cited by applicant]
WO WO2015013252 · 2015 [cited by applicant]
U.S. Appl. No. 15/365,846, filed Nov. 30, 2016, Lee. [cited by applicant]
U.S. Appl. No. 16/127,098, filed Sep. 10, 2018, Pannu. [cited by applicant]
U.S. Appl. No. 17/410,953, filed Aug. 24, 2021, Thacker. [cited by applicant]
Steigerwald et al., “Pulse Duration Settings in Subthalamic Stimulation for Parkinson's Disease,” Movement Disorders, vol. 33, No. 1, 2018, 5 pages. [cited by applicant]
Dayal et al., “Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: The Effect of Varying Stimulation Parameters,” Journal of Parkinson's Disease 7, 2017, 11 pages. [cited by applicant]
Akbari et al., “The proposed mechanisms of radio frequency waves (RFWs) on nervous system functions impairment,” Comp Clin Patho, 2015, 13 pages. [cited by applicant]
Benabid et al., “Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of the movement disorders,” Journal of Neurosurg, 1996, 12 pages. [cited by applicant]
Benabid et al., “Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease,” www.thelancet.com/neurology, vol. 8, Jan. 2009, 15 pages. [cited by applicant]
Benabid et al., “Long-Term suppression of tremor by chronic stimulation of the ventral intermediate,” The Lancet, vol. 337, 1991, 4 pages. [cited by applicant]
Benabid et al., “Chronic Electrical Stimulation of the Ventralis Intermedius Nucleus of the Thalamus and of Other Nuclei as a Treatment of Parkinson's Disease,” Techniques in Neurosurgery, vol. 5, No. 1, 1999, 26 pages. [cited by applicant]
Cabezas et al., “The role of glial cells in Alzheimer disease: potential therapeutic implications,” Neurologia, 2014, 5 pages. [cited by applicant]
Holm et al., “Insights into Pathology of the ∞3 Na+/K+-ATPase Ion Pump in Neurological Disorders; Lessons from Animal Models,” Frontier in Physiology, 2016, 12 pages. [cited by applicant]
Kann, Oliver, “The interneuron energy hypothesis: Implications for brain disease,” Neurobiology of Disease, 2015, 11 pages. [cited by applicant]
Kinoshita et al., “The Influence of Na+, K+-ATPase on Glutamate Signaling in Neurodegenerative Diseases and Senescence,” Frontiers in Physiology, Jun. 2016, 19 pages. [cited by applicant]
Liu et al., “Activation of Na+ and K+ Pumping Modes of Na,k)-ATPase by an Oscillating Electric Field,” The Journal of Biological Chemistry, vol. 265, May 5, 1990, 9 pages. [cited by applicant]
Miller et al., “Electric Field Driven Torque in ATP Synthase,” PLoS One, vol. 8, Issue 9, Sep. 2013, 9 pages. [cited by applicant]
Tsong, Tian Yow, “Electrical Modulation of Membrane Proteins: Enforced Conformational Oscillations and Biological Energy and Signal Transductions,” Annu. Rev. Biophys. Biophys. Chem., 1990, 24 pages. [cited by applicant]
Vitvitsky et al., “Na+ and K+ ion imbalances in Alzheimer's disease,” Biochimica et Biophysica Acta, Elsevier, 2012, 11 pages. [cited by applicant]